Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Hans Michael KvasnickaJürgen ThieleCarlos E Bueso-RamosWilliam SunJorge CortesHagop M KantarjianSrdan VerstovsekPublished in: Journal of hematology & oncology (2018)
INCB18424-251, ClinicalTrials.gov identifier NCT00509899 .